Congress tightens rules on drug discounts for safety-net hospitals

What it does

This bill clarifies that drug manufacturers participating in the 340B discount program must offer discounted prices to covered entities (hospitals, clinics, health centers) regardless of how or where the drugs are dispensed—including through contract pharmacies—and prohibits manufacturers from placing conditions on these discounts. It also establishes civil penalties (up to $2 million per day) for manufacturers who violate these requirements and creates a process for covered entities to report violations.

Why we flagged it

The bill's core function is to enforce and clarify existing 340B program rules to ensure covered entities can use discounts flexibly, particularly through contract pharmacies, to maximize patient access to discounted drugs. It is a regulatory clarification and enforcement measure, not a new entitlement or subsidy.

What the text implies

• Manufacturers may face significant compliance costs and legal exposure if they have been conditioning 340B discounts on dispensing location or method; the $2M/day penalty creates strong incentive to cease such practices immediately.
• Contract pharmacies—particularly specialty and mail-order pharmacies serving rural or underserved areas—may see increased volume and revenue as covered entities gain clearer legal authority to use them without manufacturer interference.
• The bill does not expand the 340B program itself but removes manufacturer-imposed barriers; the actual expansion of patient access depends on covered entities' willingness and capacity to use contract pharmacies.
• Manufacturers may attempt to challenge the bill's interpretation of existing 340B statute in court, arguing the amendments exceed congressional intent or constitute an uncompensated taking; litigation risk is material.
• The 180-day regulatory timeline for enforcement standards and violation claims processes may create a gap period during which manufacturers test compliance boundaries before rules are finalized.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill protects patient access to discounted drugs by preventing manufacturers from blocking or restricting how covered entities use 340B discounts, particularly through contract pharmacies that serve patients in underserved areas. Enforcement mechanisms and clearer rules reduce manufacturer leverage to circumvent the program's intent to stretch limited healthcare resources.

Who stands to gain

• covered entities (hospitals, clinics, health centers)
• contract pharmacies (specialty and mail-order)
• patients accessing discounted drugs

Named in the bill

340B program, Public Health Service Act, covered entities, drug manufacturers, contract pharmacies, HHS Secretary, Medicare Part D, Medicaid, Bristol Myers Squibb (BMY), Gilead Sciences (GH), Pfizer (PFE), DaVita (DVA) — and 1 more

Where it stands

21 cosponsors: 21 Democrats.

• Jul 22, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 22, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

12 lobbying clients named this bill on 17 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $9,965,651 in lobbying spend. A filing names 16 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 93% of bills with at least one filing.

Doris Matsui, the sponsor, reported $1,026,688 in PAC receipts in the 2026 cycle.

• American Hospital Association — $4,470,000 on 1 filing
• Pfizer Inc. — $1,720,000 on 1 filing
• University of California — $1,140,000 on 1 filing
• Trinity Health — $720,000 on 3 filings
• American Society of Health-system Pharmacists — $510,000 on 2 filings

Lobbying Disclosure Act filings through Jul 24, 2026. A filing shows who paid to lobby on a bill it names, not what changed.